Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy
Cells · 2025
DOI: 10.3390/cells14130971 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Ulas Kumbasar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Faculty of Medicine, Hacettepe University, Ankara 06100, Türkiye. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Perioperative Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Nonetheless, deeper molecular understanding of NSCLC has resulted in novel therapeutic approaches, including targeted therapy and immunotherapy, which have improved patient prognosis and outcomes in recent years. Immune checkpoint inhibitors (ICIs), with or without chemotherapy, are now considered valuable components of treatment for NSCLC cases that do not have specific actionable genetic mutations. Patients with actionable genetic mutations are candidates for targeted therapies. The primary focus of this review is the rationale for using ICIs in the perioperative setting for patients with resectable NSCLC and in advanced disease settings. Furthermore, we compare the benefits of using ICIs with the challenges associated with their clinical implementation in resectable and advanced NSCLC. Finally, we emphasize the development of novel treatment strategies that potentially provide an optimal treatment choice for patients with advanced NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Faculty of Medicine, Hacettepe University, Ankara 06100, Türkiye.
- Department of Medical Biochemistry, Faculty of Medicine, Hacettepe University, Ankara 06100, Türkiye.
- Department of Research and Development, MAIA Biotechnology, Inc., Chicago, IL 60606, USA.
- Medical Oncology, Yildirim Beyazit University, Ankara 06800, Türkiye.
- Medical Oncology, Liv Hospitals, Istinye University, Ankara 06800, Türkiye.
ORCID-Profile: Zeliha Gunnur Dikmen, Ates Tenekeci, Ilgen Mender, Sergei Gryaznov
Zitieren
APA
Kumbasar, U., Dikmen, E., Dikmen, Z. G., Tenekeci, A., Mender, I., Gryaznov, S., Bilgin, B., & Kilickap, S. (2025). Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy. Cells. https://doi.org/10.3390/cells14130971
Vancouver
Kumbasar U, Dikmen E, Dikmen ZG, Tenekeci A, Mender I, Gryaznov S, et al. Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy. Cells. 2025. doi:10.3390/cells14130971
BibTeX
@article{Kumbasar2025,
author = {Kumbasar, Ulas and Dikmen, Erkan and Dikmen, Zeliha Gunnur and Tenekeci, Ates and Mender, Ilgen and Gryaznov, Sergei and Bilgin, Burak and Kilickap, Saadettin},
title = {Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14130971}
}
EUVIMED